Welcome to our dedicated page for Si-Bone news (Ticker: SIBN), a resource for investors and traders seeking the latest updates and insights on Si-Bone stock.
SI-BONE, Inc. reports developments for a medical device business focused on procedural solutions for compromised bone and sacropelvic disorders. The company develops technologies centered on spinopelvic anatomy, including applications in minimally invasive SI joint fusion, adult spinal deformity, spinopelvic and sacropelvic fixation, and pelvic trauma.
Recurring updates include quarterly and annual financial results, revenue guidance, cash flow and adjusted EBITDA commentary, physician adoption metrics, reimbursement developments, and healthcare conference presentations. Product references include the iFuse Implant System, iFuse Bedrock Granite, iFuse TORQ, iFuse TORQ TNT, iFuse 3D, and related surgical implant technologies.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
SANTA CLARA, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- SI-BONE, a leader in musculoskeletal disorder solutions, will participate in the 2023 Bank of America Merrill Lynch Global Healthcare Conference. The event features a management fireside chat on May 9, 2023, at 1:55 p.m. Eastern Time. A live webcast will be accessible via the company's website with a 90-day post-event archive available for replay.
SI-BONE, known for the iFuse Implant System, has pioneered minimally invasive surgical treatments for SI joint disorders since 2009. With nearly 80,000 procedures performed by over 3,000 surgeons, SI-BONE enjoys wide insurance coverage for these treatments. This position enables continued advancements in clinical research and the commercialization of new surgical solutions for pelvic disorders.